Lupin pharmaceuticals is a U.S based company which is among top 5 pharmaceuticals companies in India. Through sales, Lupin Pharmaceuticals Inc. is dedicated to delivering high-quality, branded and generic medications trusted by healthcare professionals and patients across geographies.
Lupin Limited headquartered in Mumbai India, is focused mainly in research. The company R&D centre are in Pune and is a leading global player in Anti-TB, Cephalosporin’s and Cardiovascular drugs and has a notable presence in the areas of diabetes, anti-inflammatory and respiratory therapy.
Lupin’s R&D covers:
· Generics Research
· Process Research
· Pharmaceutical Research
· Advanced Drug Delivery Systems (ADDS) Research
· Intellectual Property Management
· Novel Drug Discovery and Development (NDDD)
· Biotechnology Research
Vinita Gupta, CEO of Lupin Pharmaceuticals, Inc. says “we founded on the strengths of our parent company Lupin Limited, Lupin Pharmaceuticals Inc. intends to bring a portfolio of generics as well as branded products to the US market."
Lupin pharmaceutical are divided into various products generics, speciality and API. It provides advance manufacting technology and process mainly focuses on generic products. It has manufacturing operations in 5 cities in India and also a site in Thailand. Our plants are located at Mandideep, Aurangabad, Tarapur, Ankleshwar and Goa, in India.
Research is to be the main driver for success of Lupin Pharmaceuticals; Inc. Research is the foundation upon which Lupin Pharmaceuticals, Inc. will participate in a variety of therapeutic areas.
The company has achieved many accomplishments such as:-
· Successful US FDA inspection at 11 manufacturing facilities
· Asia's only US FDA approved fermentation plant for rifampicin.
· WHO certified finished products manufacturing facility for tuberculosis products.
Facts about Lupin pharmaceuticals ltd:-
· The Lupin Research Park is located at Pune, India.
· 19 acre site with built area of 150,000 sq.
· Home to 320 scientists.
· Lupin's core site for innovation:
· Process development;
· Technology development;
· Basic preclinical, phase1 and phase 2 research.
· 145 patents filed, 53 patents granted worldwide.
In business development, Lupin was founded to meet the very basic need for effective treatment of tuberculosis. Our success is tied to continually meeting the need for basic products to promote human health. Our company strives to bring important new products to market each year. We expect our products to come from:
· In-house product development;
· Licensing and acquisitions;
· Marketing alliances.
About Lupin’s founder:-
Lupin was founded in 1968 by Desh Bandhu Gupta, then an Associate Professor at BITS-Pilani, Rajasthan. Named after the Lupin flower because of its inherent qualities and what it personifies and stands for, the company was created with a vision to fight life-threatening infectious diseases and to manufacture drugs of the highest social priority.
Lupin first gained recognition when it became one of the world’s largest manufacturers of tuberculosis drugs.
The company today has a significant market share in key markets in the cardiovascular, Dialectology, asthma, paediatrics, CNS, GI, anti-infectives and NSAIDs therapy segments. The company’s R&D endeavours have resulted in significant progress in its new chemical entity (NCE) program.
Lupin’s foray into advanced drug delivery systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals.
Its manufacturing facilities, spread across India and Japan, have played a critical role in enabling the company realize its global aspirations. Benchmarked to International standards, these facilities are approved by international regulatory agencies including the US FDA, UK MHRA, Japan’s MHLW, TGA Australia, WHO, and the MCC South Africa.
In July 2015 the company announced its intention to acquire Gavis Pharmaceuticals and Novel Laboratories for $880 million.